ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric Cas-CLOVER. Dublin, Ireland and Kentucky, USA, September 12: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio (‘Demeetra’). This.
Read Full ArticleSchedule time with:
Michael Arciero, Vice President IP & Commercial Development
‘This is a lot of misinformation in circulation when it comes to the CRISPR licensing landscape. In speaking at LSPN, my goal is to cut through the noise and provide straightforward answers to common misperceptions.’
